Intellia Therapeutics
Clinical trials sponsored by Intellia Therapeutics, explained in plain language.
-
Gene-Editing shot aims to stop sudden swelling attacks
Disease control OngoingThis study tests a one-time gene-editing therapy called NTLA-2002 for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. About 80 participants aged 16 and older will receive either the treatment or a placebo to see if it reduces the…
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:23 UTC
-
Gene therapy for HAE: Long-Term Follow-Up begins
Disease control ENROLLING_BY_INVITATIONThis study follows 100 people with hereditary angioedema (HAE) who previously received the experimental gene therapy NTLA-2002. Researchers will track side effects and how well the treatment controls swelling attacks over time. The goal is to understand the long-term safety and l…
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Gene therapy aims to stop painful swelling attacks in rare disease
Disease control OngoingThis study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene-editing to reduce a protein that triggers attacks. Researchers are checking safety and how well it works …
Phase: PHASE1, PHASE2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:02 UTC